Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Tax Provisions (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Tax Provisions for 10 consecutive years, with $501000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions fell 96.74% year-over-year to $501000.0, compared with a TTM value of $3.4 million through Dec 2025, down 77.56%, and an annual FY2025 reading of $3.4 million, down 77.56% over the prior year.
  • Tax Provisions was $501000.0 for Q4 2025 at Zevra Therapeutics, up from -$433000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $15.4 million in Q4 2024 and bottomed at -$715000.0 in Q2 2022.
  • Average Tax Provisions over 5 years is $1.2 million, with a median of -$4000.0 recorded in 2022.
  • The sharpest move saw Tax Provisions plummeted 2475.0% in 2023, then skyrocketed 3041.43% in 2025.
  • Year by year, Tax Provisions stood at $34000.0 in 2021, then tumbled by 200.0% to -$34000.0 in 2022, then skyrocketed by 620.59% to $177000.0 in 2023, then skyrocketed by 8584.18% to $15.4 million in 2024, then crashed by 96.74% to $501000.0 in 2025.
  • Business Quant data shows Tax Provisions for ZVRA at $501000.0 in Q4 2025, -$433000.0 in Q3 2025, and $2.2 million in Q2 2025.